Inquis Medical’s Aventus Thrombectomy System Studied to Treat Pulmonary Embolism

May 6, 2025—Inquis Medical recently announced that the AVENTUS trial evaluating the company’s investigational Aventus thrombectomy system met its primary endpoints, demonstrating both safety and efficacy in the treatment of acute intermediate-risk pulmonary embolism (PE).

Jun Li, MD, presented the findings during the late-breaking clinical trial session at the Society for Cardiovascular Angiography & Interventions’ SCAI 2025 scientific sessions held May 1-3 in Washington, DC. The SCAI abstract is available online here. The findings were simultaneously published online by Saher Sabri, MD, et al in JSCAI. Dr. Li and Dr. Sabri are national coprincipal investigators of the AVENTUS Trial, noted the company.

According to Inquis, the prospective, single-arm, multicenter AVENTUS trial included 49 investigators who enrolled 130 patients across 22 sites in the United States. The investigators enrolled patients (age, 18-80 years) with symptomatic CTA-documented acute intermediate-risk PE of ≤ 14 days duration. Intermediate-risk PE was defined as right ventricle/left ventricle (RV/LV) ratio ≥ 0.9 per international guidelines.

As summarized in the company’s press release, the results showed significant improvement in RV function, reduction in clot burden, minimal blood loss, short intensive care unit (ICU) stays, and short total hospital stays with no device-related major adverse events (MAEs). Additionally, there were meaningful improvements in patient-reported quality of life and a significant increase in 6-minute walk test distance through 30 days, according to Inquis.

Inquis reported that the AVENTUS trial met its primary safety endpoint with zero device-related MAEs within 48 hours compared to the performance goal of 25% (P < .0001). The primary safety endpoint was defined as the rate of device-related MAEs (a composite of death, major bleeding, clinical deterioration, pulmonary vascular injury, or cardiac injury).

The primary efficacy endpoint was met with patients demonstrating a mean 0.47 reduction in core lab-assessed RV/LV ratio from baseline to 48 hours postprocedure (P < .0001). Additional efficacy measures included a 35.9% improvement in refined Modified Miller Index, adjudicated by the core laboratory at 48 hours postprocedure. The trial also reported a mean ICU stay of 0.8 days, with 68.9% of patients discharged from the ICU in < 24 hours, stated Inquis.